Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial MarketWatch (press release) Low-dose tacrolimus was given for temporary immune-suppression from the time of injection for 46 days, at which point the dose was tapered and withdrawn completely at 60 days. Endpoints of the trial are safety and evaluation of neurological function, ... |
